Key Takeaways
Multiple law firms have announced a class-action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO), giving investors who suffered losses until May 5, 2026, to apply for the lead plaintiff role.
"According to the Complaint, Soleno and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws," stated a press release from Kahn Swick & Foti, LLC.
The lawsuit alleges that Soleno misrepresented and concealed evidence of significant safety concerns related to its lead product, DCCR, a treatment for Prader-Willi syndrome. The filings specify that the company downplayed risks of "excessive fluid retention" observed in clinical trial participants, presenting a misleading picture of the drug's commercial viability. The class period covers investors who purchased stock from March 26, 2025, to November 4, 2025.
The legal action, titled City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., claims that when the true safety profile of DCCR became known, investors suffered damages. The case creates legal and financial uncertainty for Soleno, whose commercial prospects hinge on DCCR, its sole product candidate.
The core of the allegations is that the company's failure to disclose the safety issues artificially inflated its stock price. Law firms including Rosen Law Firm and The Gross Law Firm have also issued notices encouraging affected shareholders to join the case.
This lawsuit follows a period where the company's disclosures about its Phase 3 clinical trial program for DCCR are now under scrutiny. The outcome of the case could impact Soleno's ability to bring DCCR to market and expose it to significant financial damages. Investors will be watching for the company's formal response to the complaint and any subsequent court filings ahead of the May 2026 deadline.
This article is for informational purposes only and does not constitute investment advice.
